HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

HDL2 Lipoproteins

Low-density subclass of the high-density lipoproteins, with particle sizes between 8 to 13 nm.
Also Known As:
Lipoproteins, HDL2; HDL-2; HDL2 Lipoprotein; High Density Lipoprotein HDL2; Lipoprotein HDL2; HDL 2; HDL2, Lipoprotein; High Density Lipoprotein 2; Lipoprotein, HDL2; High Density Lipoprotein-2
Networked: 67 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. McEneny, Jane: 3 articles (02/2013 - 01/2013)
2. McGinty, Ann: 3 articles (02/2013 - 01/2013)
3. Young, Ian S: 3 articles (02/2013 - 01/2013)
4. Moriyama, Kengo: 2 articles (06/2016 - 11/2014)
5. Takahashi, Eiko: 2 articles (06/2016 - 11/2014)
6. McMaster, Cyril: 2 articles (02/2013 - 01/2013)
7. Wade, Lauren: 2 articles (02/2013 - 01/2013)
8. Ebenbichler, C F: 2 articles (10/2004 - 06/2001)
9. Kaser, S: 2 articles (10/2004 - 06/2001)
10. Patsch, J R: 2 articles (10/2004 - 06/2001)

Related Diseases

1. Dyslipidemias (Dyslipidemia)
09/01/2023 - "This study demonstrates that the HDL subfraction profile (especially the decrease in HDL-2 and -L) may be a useful marker for the early detection and intervention of atherogenic dyslipidemia in subjects with impaired glucose and insulin metabolism."
01/01/2020 - "The KD-fed rats showed a tendency to develop dyslipidemia as evidenced by elevated Total Cholesterol /HDL and LDL/HDL (2.32±0.32 and 1.19±0.08) in group III, which was reversed in the KD+Mg fed group IV (1.96±0.32 and 1.08±0.09) with p<0.05. "
05/01/1999 - "Insulin resistance is associated with dyslipoproteinemia characterized by increased serum triglycerides, reduced high-density lipoprotein 2 (HDL2) cholesterol, and increased small, dense low-density lipoprotein (LDL) subfraction particles. "
09/01/2002 - "These data indicate that in diabetic patients, extended-release niacin (1) is effective for separately treating diabetic dyslipidemias associated with abnormal LDL size, HDL-2, and Lp(a) independently of glycated hemoglobin levels; (2) must be used with modern and aggressive oral hypoglycemic agents or insulin treatment; and (3) is a major drug for the treatment of diabetic dyslipidemias because of its broad spectrum of effectiveness for the ALP and Lp(a)."
11/01/1995 - "Obesity, insulin resistance (IR) with hyperinsulinemia, and a dyslipoproteinemia characterized by reduced high-density lipoprotein 2 (HDL2) cholesterol and elevated levels of small, dense low-density lipoprotein (LDL) particles are risk factors for coronary artery disease (CAD). "
2. Weight Loss (Weight Reduction)
3. Hypertriglyceridemia
4. Spinocerebellar Ataxias (Spinocerebellar Ataxia)
5. Progressive Myoclonic Epilepsies (Progressive Myoclonic Epilepsy)

Related Drugs and Biologics

1. oxidized low density lipoprotein
2. Apolipoproteins B (ApoB)
3. Insulin (Novolin)
4. Lipoproteins (Lipoprotein)
5. 1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)
6. Niacin (Nicotinic Acid)
7. Hypoglycemic Agents (Hypoglycemics)
8. Glycated Hemoglobin (Glycosylated Hemoglobin)
9. HDL3 Lipoproteins
10. Cholesterol

Related Therapies and Procedures

1. Bariatric Surgery
2. Ligation
3. Renal Dialysis (Hemodialysis)